HomeCompareHBRM vs ARCC

HBRM vs ARCC: Dividend Comparison 2026

HBRM yields 2000000.00% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBRM wins by $4.879226400974806e+39M in total portfolio value
10 years
HBRM
HBRM
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full HBRM calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — HBRM vs ARCC

📍 HBRM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBRMARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBRM + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBRM pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBRM
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, HBRM beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBRM + ARCC for your $10,000?

HBRM: 50%ARCC: 50%
100% ARCC50/50100% HBRM
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

HBRM
No analyst data
Altman Z
-163.3
Piotroski
2/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBRM buys
0
ARCC buys
0
No recent congressional trades found for HBRM or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBRMARCC
Forward yield2000000.00%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$4.879226400974806e+39M$24.5K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$1.16
Total dividends collected$4.879195005460081e+39M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: HBRM vs ARCC ($10,000, DRIP)

YearHBRM PortfolioHBRM Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,381$541.15+$200.00MHBRM
2$3,738,731,768,458$3,738,517,757,009.35$12,621$284.08+$3738731.76MHBRM
3$65,315,062,866,930,490$65,311,062,423,938,240.00$13,827$145.31+$65315062866.92MHBRM
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$15,062$73.43+$1066400830062625.00MHBRM
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$16,364$36.89+$16272182796453826560.00MHBRM
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$17,757$18.49+$2.3205424011366188e+23MHBRM
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$19,258$9.25+$3.0927990661046884e+27MHBRM
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$20,880$4.63+$3.8524105697352695e+31MHBRM
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$22,636$2.32+$4.484688260147987e+35MHBRM
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$24,539$1.16+$4.879226400974806e+39MHBRM

HBRM vs ARCC: Complete Analysis 2026

HBRMStock

Herborium Group, Inc., a botanical therapeutics company, develops, licenses, and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. It offers dermatology products, which include AcnEase, herbal medicinal product for enhancing conditions associated with hormonal acne and multiple symptoms of Rosacea; and AcnEase Skin Management System for the treatment of acne marks/scars. The company also provides sexual health and performance products that are non-prescriptive alternatives to selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, and surgical procedures, including hysterectomy. In addition, it offers energy restoration products, such as Lasting Energy, a herbal supplement to decrease the symptoms associated with hangovers and eliminating jet-lag; and for treating overall depletion of energy due to competitive sports, high levels of stress, and extensive sexual activities, as well as other long term or temporary physical demands. Further, the company provides Liver Activator Series for the treatment of liver damage; ProstAid, a natural product focuses on Benign Prostate Hyperplasia; and CardioVitae, a fermentation based product using a Lucidium derived cell line targeting cardio-pulmonary insufficiencies. Herborium Group, Inc. sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. The company was founded in 2000 and is headquartered in Fort Lee, New Jersey.

Full HBRM Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this HBRM vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBRM vs SCHDHBRM vs JEPIHBRM vs OHBRM vs KOHBRM vs MAINHBRM vs HTGCHBRM vs GBDCHBRM vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.